MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on July 26, 2005; DOI: 10.1124/mol.105.017277

This Article
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.105.017277v1
mol.105.017277v2
68/4/952    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akassoglou, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akassoglou, K.


Received for publication July 26, 2005.
Revised July 25, 2005.
Accepted for publication July 26, 2005.

NGF requirement for neuronal survival? NO thanks! (Relates to Article by Culmsee, et al. FastForward 18 July 2005)

Katerina Akassoglou 1*

1 University of California, San Diego

* Address correspondence to: E-mail: aakasoglou{at}ucsd.edu

Abstract

Due to the limited therapeutic applications of Nerve Growth Factor (NGF), there has been increasing focus on the development of pharmacological tools to bypass the requirement of NGF for the activation of the TrkA tyrosine kinase receptor neuronal survival pathway. In this issue of Molecular Pharmacology, the work by Culmsee et al. shows that activation of TrkA by protein tyrosine phosphatase (PTP) inhibitors is only achieved when accompanied by release of nitric oxide (NO). This work identifies the NO/cGMP/PKG pathway as a signal transduction pathway that is integrated with NGF/TrkA to induce activation of Akt and ERK1/2 and mediate neuronal survival in the absence of NGF. In addition, it underscores the potential therapeutic effects of Ethyl-3,4-dephostatin (DPN), a stable analogue of the naturally occurring PTP inhibitor dephostatin, that serves as a NO-donor and protects neurons from apoptosis.


Key words: Adenosine, NGF/EGF, Guanylyl cyclase, Nitric oxide, Nitric oxide synthases, Protein Kinase G, Excitotoxicity, neurodegeneration


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
D. M. Wilcock, M. R. Lewis, W. E. Van Nostrand, J. Davis, M. L. Previti, N. Gharkholonarehe, M. P. Vitek, and C. A. Colton
Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2
J. Neurosci., February 13, 2008; 28(7): 1537 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. B. Arthur, S. Georgi, K. Akassoglou, and P. A. Insel
Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival.
J. Neurosci., April 5, 2006; 26(14): 3798 - 3804.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics